Valeant Pharmaceuticals says it will upgrade its unsolicited bid to buy specialty drugmaker Allergan for nearly $46 billion, and it wants to tell Allergan shareholders why it offers the better deal. The Canadian drugmaker says it will host a webcast later this month to explain why the cash-and-stock offer it announced last month is better than Allergan’s plan to continue running as a stand-alone company. Valent says it will improve its offer to show its commitment to getting a deal done.
Help employers find you! Check out all the jobs and post your resume.
